There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on SAGE Therapeutics (NASDAQ: SAGE) and MacroGenics (NASDAQ: MGNX) with bullish sentiments.
SAGE Therapeutics (NASDAQ: SAGE)
In a report released yesterday, Ritu Baral from Cowen & Co. maintained a Buy rating on SAGE Therapeutics (NASDAQ: SAGE), with a price target of $207. The company’s shares opened today at $157.22.
According to TipRanks.com, Baral is a top 25 analyst with an average return of 34.3% and a 55.9% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, ACADIA Pharmaceuticals Inc, and Allena Pharmaceuticals Inc.
Currently, the analyst consensus on SAGE Therapeutics is Strong Buy and the average price target is $215.50, representing a 37.1% upside.
In a report issued on April 23, BMO Capital also reiterated a Buy rating on the stock with a $203 price target.
See today’s analyst top recommended stocks >>
MacroGenics (NASDAQ: MGNX)
Cowen & Co. analyst Boris Peaker maintained a Buy rating on MacroGenics (NASDAQ: MGNX) yesterday. The company’s shares opened today at $20.18.
According to TipRanks.com, Peaker is a 5-star analyst with an average return of 18.2% and a 52.3% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals Inc, Stemline Therapeutics Inc, and Mersana Therapeutics Inc.
Currently, the analyst consensus on MacroGenics is Strong Buy and the average price target is $30.75, representing a 52.4% upside.
In a report released yesterday, BTIG also maintained a Buy rating on the stock with a $28 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
